20 citations
,
December 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”
Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
The user has been treating hair loss with 1mg oral finasteride daily, 1mg topical minoxidil twice daily, and microneedling twice a week. They report improved hair quality and density but are still experiencing shedding.
A person treated their diffuse alopecia with oral minoxidil (10mg daily), oral finasteride (reduced to 0.25mg daily due to side effects), castor oil, vitamins, and ashwagandha, and plans a hair transplant in Turkey. They stopped using topical minoxidil, have seen improved hair density, but are still experiencing hair loss.
Accepting hair loss, with solutions discussed including Minoxidil and Finasteride treatments, shaving the head as a liberating experience, and using beards to make up for lack of hair.
Hair loss treatments, specifically the use of Finasteride, Nizoral, and dermarolling; potential results from these treatments are discussed, along with potential side effects.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.